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TO STUDY THE SEROPREVALENCE OF HEPATITIS E VIRUS
INFECTION IN ASYMPTOMATIC PREGNANT MOTHERS
ATTENDING ROUTINE ANTENATAL CHECK UP IN A
TERTIARY CARE HOSPITAL
OBJECTIVES: HEV infection in pregnant women is more common and
fatal in the third trimester. In India there is very less data documented with
respect to seroprevalence of HEV in pregnant mothers.The present study
was designed to determine the seroprevalence of subclinical HEV infection
in asymptomatic pregnant women.
METHODS:200 asymptomatic pregnant womenwith no history of jaundice
were studied. Prevalence of anti-HEV antibodies was determined by ELISA
and Seminested reverse transcriptase PCR.
RESULTS: The overall seroprevalence of HEV IgM and IgG were 18
(9%)and IgM 12 (6%) in asymptomatic pregnant women. Among them only
IgM+ cases were 5 (2.5%), only IgG+ were 11 (5.5%) and both IgM+&IgG+
were 7 (3.5%). No HEV-RNA was detected by RTPCR, which was done for
90 negative cases and all IgM positive cases. This confirms no viremia in the
blood and hence no patients were in the window period or active infection.
HEV-RNA testing can be considered in patients who are symptomatic for
hepatitis E infection because viremia is the only marker of infection during
the acute phase where anti HEV antibodies were not in a detectable levels.
INTERPRETATION & CONCLUSIONS: Present study conducted in
Chennai, showed low level of HEV seroprevalence compared to north India.
Seroprevalence was significantly associated with overcrowding, type of
toilet facility and habit of hand washing with soap after using toilet. As
hepatitis E virus spread through faeco-oral contamination, Conservative
control efforts at the community level must be undertaken. As HEV is a
vaccine preventable infection, it can be considered in the most susceptible
and high-risk groups in endemic countries. Early preventive measures if
taken, may decrease the maternal and perinatal mortality and morbidity of
HEV infection.
8INTRODUCTION
Hepatitis is the condition characterized by the presence of
inflammatory cells in the liver tissue. It is caused by different
aetiological agents and is more commonly used to refer to a group of
viral infections that affects liver, such as hepatitis A, B, C, D and E.
Hepatitis A and E are transmitted through faeco-oral route, hepatitis B
and C are transmitted through infected blood and body fluids and
hepatitis D occur exclusively in persons infected with hepatitis B virus.
All water borne epidemic viral hepatitis were thought to
be caused by hepatitis A virus. In Delhi there was a suspected outbreak
of hepatitis A between 1955 and 1956. Serum samples from those
patients were collected and preserved. In 1983 a specific and sensitive
assay was applied to these preserved samples and they were found to
be negative for specific antibodies against hepatitis A virus4. Thus a
new clinical entity came into life with signs and symptoms similar to
other forms of viral hepatitis.
It was designated as hepatitis E because of its enteric
transmission, epidemic and endemic nature that capture the hepatitis E
virus1. Later it was known as Enterically Transmitted Non A Non B
(ENANB) hepatitis or Epidemic Non A Non B5.
9Hepatitis E virus (HEV) causes large outbreaks in endemic areas
like India, Central Asia, parts of Africa and Mexico1. It is the most
important cause of epidemic and sporadic viral borne hepatitis in
countries with suboptimal sanitary conditions affecting susceptible
population like young aged adults and pregnant women.
Prevalence of Hepatitis E in developing countries ranges from
7.2% to 24.5% when compared to <1% in developed countries25,32.
Hepatitis E virus causes an acute short lived, self-limiting viral
hepatitis typically lasting for 1-4 weeks. It affects both sexes targeting
age group between 15 and 40. It exhibits a wide clinical spectrum,
fluctuating from asymptomatic infection to fulminant hepatitis. Most
cases of pregnancy will not affect the severity of hepatitis unless it is
found to be hepatitis E which tends to worsen during the period of
pregnancy. It causes fulminant hepatic failure (FHF) in pregnant
women particularly those in 2nd and 3rd trimester of pregnancy. There is
a high rate of occurrence of disseminated intravascular coagulation
(DIC) associated with hepatitis E infection in pregnancy27. Attack rate
among 1st, 2nd and 3rd trimester were 8.8%, 19.4% and 18.6%
respectively. Whereas among non-pregnant women and men it is only
2.1% and 2.8%2.
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37% of acute viral hepatitis during pregnancy is caused by
hepatitis E and 81% of them go in for fulminant hepatic failure more
commonly during 3rd trimester of pregnancy20,22.  General mortality
rate in hepatitis E is 1 to 2 percentage when compared with hepatitis A
which is 0.4 percentage1.
The case fatality rate among pregnant mothers is 25% 4,22,25 and
has been reported to be very high with maximum severity in the third
trimester of pregnancy i.e. 44.4%2 .In fact, the major cause of mortality
in epidemics is due to the high rate of fulminant hepatic failure in
pregnant women27. Besides the high maternal mortality rate, the other
dangers of fulminant hepatic failure such as fetal malformation,
abortion, still birth and neonatal death are noted among pregnant
mothers with hepatitis E infection4,25.
High rates of vertical transmission of hepatitis E were
documented between 33.3% and 50% leading to high fetal mortality25.
Studies have reported that 78.9% of babies had evidence of vertically
transmitted HEV infection30. This data points to a relationship between
severity of HEV infection in the pregnant women and the fetus.
Most of the cases of hepatitis E remain asymptomatic. The
treatment of acute infection is supportive management. In spite of the
explosive nature of hepatitis E during pregnancy, there is no
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established treatment available for it31. Therapeutic termination of
pregnancy as approved in disorders like HELLP syndrome have not
been completely explored in hepatitis E infection19. The diagnosis of
hepatitis E infection in individual patients remains challenging. It
cannot be clinically distinguished from other forms of acute viral
hepatitis. The routine laboratory diagnosis of hepatitis E is based either
on serologic tests or nucleic acid amplification techniques27.
Trials of HEV vaccines are presently continuing in many
countries. This consists of a candidate vaccine which is very effective
and accepted in China, showing efficacy of >90%. On January 23,
2012 this vaccine has been licensed by State Food and Drug
Administration of China for its production and sale. Perhaps it is a
major milestone on the road towards protecting susceptible women in a
disease endemic country like India.
Hepatitis E is accountable for approximately 9.8% of pregnancy
associated deaths. In southern Asia, as many as 10,500 maternal deaths
per year could be prevented by using the existing vaccine24. With the
availability of an efficacious vaccine, we must consider prudent
implementation of such an intervention, where appropriate, to avoid a
significant proportion of preventable deaths in developing countries.
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This study is to assess the seroprevalence of subclinical hepatitis
E viral infection in asymptomatic pregnant mothers attending routine
antenatal check up in a tertiary care hospital in Chennai. As there is
very less data documented with respect to seroprevalence of hepatitis E
in pregnant mothers in India. Moreover, it helps in considering
vaccination for the pregnant mothers and development of existing
vaccine.
Since hepatitis E infection is a significant health problem in the
world, there is a need for more public health involvement by provision
of clean drinking water, health education of public and easy
availability of approved serological assay for early detection of
infection.
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AIM AND OBJECTIVE
To study the seroprevalence of Hepatitis E virus infection in
asymptomatic pregnant mothers attending routine antenatal check up in
a tertiary care hospital in Chennai.
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REVIEW OF LITERATURE
BACKGROUND
The first description of the clinical features viral hepatitis is
recognized by Hippocrates in 460-375 BC.  Epidemics of jaundice
have been the feature of many army campaigns and have been
responsible factor for downfall and triumph of historical wars. In the
year 1965, Blumberg et al made a discovery of Australia antigen which
consequently led to the uncovering of hepatitis B virus. In 1973,
Feinstone et al visualized hepatitis A virus by immune electron
microscopy (IEM) in stool extracts of patients with acute hepatitis A
virus infection. From post-transfusion patients, Choo et al identified
hepatitis C virus and developed serological test for its diagnosis29.
Until 1980 all water borne epidemic viral hepatitis disease were
thought to be caused by hepatitis A. In 1955-56 an epidemic of
estimated 29,300 jaundice occurred in Delhi which was reported as a
typical cases of hepatitis A disease by Indian Council of Medical
Research13, though diagnostic tests for hepatitis A virus were not
existing to confirm or disprove the diagnosis. Following that in
November, 1978, in Baramulla District of Kashmir valley a large scale
epidemic of jaundice was reported in over 200 villages, covering a
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population of 6 lakhs involving icteric disease in 20,000 individuals
and with 600 deaths. The disease mainly targeted young adults and
documented maximum severity in pregnant women16. They recorded
notable conclusions13:
o The disease was caused by a hepatitis virus
o The epidemic curve compacted lasting for less than 6
weeks
o The spread was through contaminated water
o It was of non-A, non-B type
o It involved young adults with sparing of children
o Typically showed high incidence and severity in pregnant
women
o Characteristic histological findings.
In 1980, analysis of the sera collected during these epidemic
with a specific and sensitive assay were found to be negative for
specific antibodies against hepatitis A 4. Thus a new clinical entity
came into life with signs and symptoms of other forms of viral
hepatitis was known as non-A, non-B hepatitis. Indeed, very small
number of water born viral hepatitis epidemic in Asia and Africa had
been linked to hepatitis A 4.
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Later in  1991  One  of  the  biggest  waterborne  hepatitis  E
epidemic  occurred  in Kanpur  city,  Uttar  Pradesh,  India.   79,000
clinical cases have been documented. The source of this outbreak was
outlined to faecal contamination of drinking water supplied from the
river Ganges.
The experimental evidence for the presence of hepatitis E was
first reported by Balayanet al5 in the year 1983. He successfully
demonstrated the fecal-oral transmission of hepatitis. The volunteer
who had been already infected with hepatitis A infection in the past
was given a suspension inoculated with feces specimen collected from
the patient named Tashkent resident of Uzbekistan5.
By 36th day after ingestion of the infected suspension the
volunteer developed clinical feature of severe hepatitis. Between 28th
to 45th days, fecal sample was collected from the volunteer in which 27
to 30 nm sized virus like particles were detected by immune electron
microscopy (IME)5. Due to proteolytic degradation smaller viral
particles are also excreted in the stool, both sizes of particles were
observed in single stool suspension6.
The volunteer failed to develop serological markers for HAV or
HBV but he did develop antibodies to virus like particles which
recognized both size of the virus detected from his faeces5, 6. Balayanet
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al also demonstrated transmission of HEV in cynomolgus monkey with
Tashkent’s faecal sample and they excreted virus like particles in their
faeces5.
This type of non-A non-B hepatitis was designated as enterically
transmitted nonAnonB (ENANB) hepatitis or epidemic nonAnonB.
Later it was found to be the major hidden cause for epidemics in many
developing countries and also cause sporadic cases of hepatitis.
In those days Immunoelectron microscopy and transmission to
primates were the only means of studying ENANB.
CLASSIFICATION
Initially hepatitis E virus (HEV) was grouped within
Caliciviridae, genus Calcivirus based on their structural
characteristics, physiochemical properties, absence of lipid envelope,
length of nucleic acid and organization of genome type 4, 6.
Phylogenetic analysis of HEV nucleotide sequence shows it was more
closely related to positive strand RNA, with much similarity to Rubella
virus, theAlphavirus super family, particularly Rubiviruses6.
Subsequently, after a long time effort HEV has been reassigned in the
new family HerpeviridaegenusHerpevirus5 or hepatitis E like viruses
in 2004 by Emerson et al5.
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HEPATITIS E VIRUS
Hepatitis E viruses are small icosahedral, symmetrical, non-
enveloped, 27-34 nm in diameter with non-segmented positive-sense,
single stranded, polyadenylated RNA (at its 3’ terminus) and has
approximately 7.5 kb genome4,7.
RNA has 5’ region of 27 nucleotide, modified with m7 G
capping and 3’ non-coding region of 65 to 74 nucleotides and three
partially overlapping forward ORF (Open Reading Frame)4, 5, 6.
GENOTYPE AND PREVALENCE OF HEPATITIS E HUMAN
STRAIN
Genotyping became common in mid-1990’s22. Hepatitis E
strains from different parts of the world were partially or  entirely
sequenced and based on the phylogenetic analysis it was found that
there were four major human HEV strains i.e., I, II, III, IV5. Up to 9
genotypes have been proposed based on the limited sequence within
the ORF1 region6. By Schlauder and Mushahwar, 2001, homology of
isolates of the same genotype is not supposed to be less than 81%7.
Further phylogenetic analysis divided HEV genotype I into 5
subtypes, genotype II into 2 subtypes, genotype III into 10 and finally
genotype IV into 7 subtypes7.
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Genotype I – Asia (eg: India, Pakistan, Myanmar, China), North
Africa.
Genotype II – Mexico, South Africa.
Genotype III - North and South America, Europe, Asia.
Genotype IV – Asia(China, Taiwan, Vietnam, Japan).
Genotype I and II cause hepatitis outbreak especially in
developing countries and Genotype I is the most common subtype in
India.  Genotype III and IV commonly cause sporadic cases in Asia.
Genotype I contains human hepatitis E strains obtained from
endemic regions. Limited sequence strains appears to belong to
genotype II. Genotype III and IV have been identified from human and
swine sources6.
MOLECULAR CHARACTERIZATION OF THE VIRUS
Most of the molecular aspects of hepatitis E were gained by in
vitro expression of recombinant proteins due to the lack of efficient
cell culture system.
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OPEN READING FRAME (ORF 1)
ORF1 begins at the 5’ terminus of the hepatitis E genome,
following long non-coding regions with 27 to 35 nucleiotide7. ORF 1 is
5,073 to 5,124 nucleotides long codes for nonstructural proteins
(polyproteins with length of 1693 amino acid) that are involved in
replication of viral genome and viral protein processing4, 5,7.
According to Konin et al 7 , ORF 1 is found to have few putative
amino acid domains in this gene are as follows:
1. Methytransferase
2. Guanyltransferase
3. Papain-like protease (alpha and rubella viruses)
4. Proline-rich hinge domain (contains hypervariable region and
thought to impart flexibility)
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5. RNA dependent RNA polymerase
6. NTP binding sequence associated with helicase activity
(related to the helicase of superfamily I)5,7
7. It has contains two more regions called X and Y domains,
whose functions are not determined.
Activity of methyltransferase and guanlytransferase are encoded
within the first half of the 5’ end and is responsible for capping the
hepatitis E viral genome and translation is initiated by capping5,6,7,28.
Capping enzyme activity was confirmed by the expression of the 1st
979 amino acids in OPF-17. The RNA dependent RNA polymerase is
encoded within the 3’ half of the ORF15,6,7.
However, to date, none of the activities of the domains have
been demonstrated.
OPEN READING FRAME 2 (ORF2)
ORF 2 begins at 37nt 3’ of the termination coding frame of
ORF1. It is composed of 1977 to 1,980 nucleotides 5. At its 5’ end
contains three glycosylation signal sequence sites, immediately
followed by a region highly basic in charge and rich in arginine. This
region is found to encode for the main structural viral capsid proteins.
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This is synthesized as a glycosylated 71 kDa, 660 amino acid
long precursor protein in the Endoplasmic reticulum. This precursor is
then translated directly or through Golgi apparatus to the cell surface.
Due to signal sequence it is modified into mature 50-kDa protein, and
it is finally processed by C terminus truncation and assembled into the
virus particles. It is more usual for the enveloped virus to have extra
saccharide than the non-enveloped viruses5,6,7.
Hepatitis E virus envelope protein form VLPs i.e., Virus like
Protein. These particles have been characterized with the help of three-
dimensional reconstruction of the structure and Cryo-electron
microscopy. In addition to the fresh virions, ORF2 forms 30 small
sized icosahedral homodimers (size and modification are not yet
determined)5,6,7.
OPEN READING FRAME 3 (ORF3)
ORF3 is the smallest and last open reading frame. It over laps
with ORF1 by 1 nucleotide at its 5’ terminal and extends up to 325 to
328 nucleotide in the ORF2 coding frame5. It is 366 to 369 nucleotides
in length, encodes for pORF protein (123 amino acid) expressed in an
intracellular manner, shown to be associated with liver cell
cytoskeleton in HIV replication4, 6.
23
Near ORF3 amino terminus, has a cysteine rich region which
binds with hepatitis E virus RNA and forms a complex with the capsid
protein pORF2 after anchoring with pORF3 protein and starts the
process of nucleocapsid self-assembly in the virus particles. Other
aspects such as assembly and release of viral progeny, some viral
protein synthesis, HEV genomic transcription remains unclear.
KEY ANTIGENS5
HEV antigens are reactive in immune electron microscopy,
enzyme linked immunosorbent assay (ELISA), western blot and
immunofluorescentmicroscopy. Major epitopes exist in the carboxy
terminal of both ORF2 and ORF3 of HEV strains. ORF3 is more
heterogeneous, whereas ORF2 is highly conserved relatively and hence
the ORF2 sequence based serological test are broadly reactive and tests
containing ORF3 are more strain specific. But exceptions exist5.
Expressed or synthetic peptides of ORF2 and PRF3 are used in
diagnostic tests. Antigens obtained from ORF2 and expressed in insect
cells or Escherichia coli have also been used to detect antibodies by
enzyme linked immunosorbent assay (ELISA) and Western blot.
Truncated proteins expressed from ORF2 in insect cells were better
than proteins expressed in Escherichia coli for detecting antibodies
against hepatitis E virus. But they fail to detect infections with new
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genetic variants of hepatitis E virus. They are also not satisfactorily
sensitive for seroepidemiological studies5.
ORF1 incorporated test are not useful for routine diagnostic
purposes, however, important for distinguishing infection-induced and
vaccine induced immune response when non replicating hepatitis E
vaccines are available commercially5.
Linear B cell epitope have been recognized in all 3 open reading
frames of hepatitis E virus. Epitope mapping of ORF2 and 3 with long
manufactured peptides in classic ELISA tests confirms the presence of
some, but not all, of the linear epitopes. This suggest that
conformational epitopes are vital in the immune response to HEV5. In
total 26 antigenic epitopes are distributed in the ORF2 gene product5.
But only 1 neutralization site has identified which is located between
449 and 607 amino acid are conformational5.
REPLICATION OF HEPATITIS E VIRUS
Little information is known about the stages of replication
because hepatitis E virus is not closely related to any other well
characterized virus and reports from conventional cell culture are
insufficient about its strategy of replication5, 6.
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However, recently, replication of hepatitis E virus have been
documented in primary cell cultures of hepatocytes obtained from
cynomologus monkeys already infected in vivo. The process of
attachment, entry and uncoating of hepatitis E virus is not determined
because of limited availability and absence of characterized and
permissive cell culture5, 6.
It is assumed that hepatitis E virus attaches to the receptors on
hepatocytes especially in the biliary tract and intestine. From the newly
uncoated virus particle, 7.2-kb genome is released. The nonstructural
proteins recognizes the capped 5’RNA after presumably translated via
cellular mechanisms5,6 and the required enzymes are provided for the
synthesis of both positive and negative strand RNA.
Cellular proteases are found to cleave ORF1 that is sequenced
with papain like protease motif, but its functions are not yet clear.
3’ end of the viral genome shown to bind with RNA dependent RNA
polymerase and ORF 2 binds to the first 76 nucleotide of the 5’
region6.
Positive sense full length genomic RNA and 2
bicistronicsubgenomic mRNA of 3.7 and 2.0kb are transcribed from
replicative full length negative strand RNA5,6.
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However, the importance of these subgenomic RNAs in
translation of ORF2 and ORF3 protein are not determined. Nothing is
known about how these processes are regulated6.
HEPATITIS E VIRUS TRANSMISSION
Hepatitis E virus is classified as one of the waterborne and
foodborne11. Most common route of transmission is faeco-oral. Most of
the epidemic serologically confirmed for hepatitis E virus have been
found to be linked with faecal contamination of drinking water. Some
sporadic hepatitis have been associated with consumption of
undercooked pork or raw/uncooked shellfish7. Consumption of
undercooked or raw meat of infected pork, beef, wild boar meat and
offal are significantly associated with hepatitis E infection12. In Japan,
undercooked deer meat and pig liver were found to be a source of acute
HEV infection28.
The spread of hepatitis E virus infection from cases to contact by
person to person contact and fomites may play a role, but this is not
always common4. This may be due to the low amount of intact
hepatitis E particles present in a patient’s stool16. Transmission of
hepatitis E virus infection through person to person contact between
family members is only one to two percentage compared to fifteen
percentage in hepatitis A7.
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Transmission via exposure to infected blood has been reported
in endemic regions. Post transfusion hepatitis E infection have also
been documented 28. Transplacental transmission of hepatitis E  virus
in third trimester of pregnancy is associated high perinatal mortality of
the newborns14.There appears to be relatively higher risk among infants
born to mothers with hepatitis E infection upto 33.3% of cases20. In a
study of 469 pregnant women with hepatitis E infection, found to have
vertical transmission up to 100%19.
Though hepatitis E virus RNA is detected in the colostrum milk,
no evidence suggest the spread of infection to offspring1. There is no
evidence for HEV transmission through sexual route4. Hepatitis E
infection has also been documented in 3 health care workers who had
treated fulminant hepatic failure due to hepatitis E in South Africa4.
Travelling history to HEV endemic region pose a high risk factor in a
number of cases.
Improper treatment of drinking water and substandard sanitation
is the major cause for hepatitis E virus outbreaks.
ZOONOTIC POTENTIAL OF HEV
A zoonotic spread of hepatitis E is not left out. Hepatitis E
infection is an emerging anthroponosis and zoonosis in the developing
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countries. Swine hepatitis E virus has ability to cause infection in pigs
and prompted subclinical hepatitis. Experimental inoculation of human
hepatitis E though intravenous route in pigs resulted in similar
effects15.  According to Meng et al., 1997, HEV isolated from pigs are
in close resemblance to 2 human hepatitis E virus recognized in the
United States (US-1 and US-2). Hsieh et al appreciated similar result
with different strain of swine hepatitis E virus 7. Cross species
infection has been shown experimentally by Meng et al. Isolates of
swine hepatitis E has been shown to communicate disease to
chimpanzees and rhesus monkey and the human hepatitis E virus US-2
strain has been shown to be infectious for pigs7. Animals like monkeys,
cows, rodents, sheep and goats are also susceptible to infection with
hepatitis E virus hence they may be a possible source of human
reservoir of hepatitis E infection12.
The recent data indicating presence of markers of hepatitis E
infection in multiple animals like pigs, deer, rats, macaques, boars
suggest the ubiquitous nature of the virus worldwide. Studies regarding
hepatitis E in endemic and non-endemic regions have reported that
antibodies to hepatitis E are present in domestic and wild animals. This
gives an indication that these animals are in contact with hepatitis E
virus or antigenically similar agents7. According to Tien et al, 44% of
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chicken and 27% of dogs in Vietnam, by Huang et al, 71% of hens in
USA, by Okamoto et al, 33% of cats in Japan and also 29% to 62% of
cows in endemic regions and 42% to 67% of sheep and goat in non-
endemic regions documented antibodies to hepatitis E7.
This has led to the theory that hepatitis E may represent a
zoonotic pathogen, limited to its ecological position until adverse
conditions such as floods, ensued faecal contamination of drinking
water. Another likelihood is that certain individuals may have extended
period of virus shedding and in that way serves as reservoir of HEV
infection.
PATHOGENESIS AND PATHOLOGY
PRIMARY HOST TARGET CELLS FOR HEV-
HEPATOCYTES4,5,6,28
The pathogenesis of Hepatitis E virus infection is not completely
understood so far due to the lack of competent cell culture system.
Most of the little knowledge about the pathogenesis of hepatitis E virus
was obtained from the studies on non-human primates28. However,
from the clinical picture and its serological events exhibited in some of
the typical cases of hepatitis E disease, certain speculative conclusion
have been arrived at about its pathogenesis. Ingestion of contaminated
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food with infected patient’s faeces is the route of primary entry of
HEV into the host5.
It is presumed that hepatitis E virus replication takes place in the
intestinal tract. But, the route by which it gains access into the liver is
not clearly known but it is supposed to be via the portal venous
circulation. It reaches hepatocytes of the liver and starts replication in
the cell cytoplasm. The virus first appears in the liver then followed by
a phase of viraemia with high concentration of the virus found in bile
and is shed in the feces. Transient viraemia and shedding of virus in
the faeces occurs for 3-4 weeks. Anti HEV IgM peaks with the
symptomatic period and persist for 3 to 6 months and after that they
become undetectable.
Anti HEV IgG appears 3 to 4 weeks post inoculation and have
been shown to persist for 2 to 13 years. During convalescent period
IgG disappears within 6 to 12 months period1. HEV RNA are detected
in the biliary duct, on the luminal aspect of the epithelial cell surface7
using in situ hybridisation. Negative –strand viral replicative RNA was
detected the small intestine, colon, spleen, lymph nodes in swine HEV
inoculated pigs8. The template RNA was also detected in liver, spleen,
stomach, small intestine, colon, tonsils, kidney and salivary glands9.
Hepatitis E virus antigens are expressed in the hepatocyte
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cytoplasm, faeces and bile. Antigens appears one week post infection
indicating viral replication. HEV can be detected in the stool a week
prior to the clinical symptoms.
It has been established that the liver injury is caused by the
immune response produced by the host to the invading hepatitis E and
not depends directly on the replication of the virus in the liver tissue.
Viremia and faecal shedding is followed by the onset of ALT elevation
and observable histopathological changes in the liver usually
correspond to the detectable levels of antibodies to hepatitis E in the
serum and decreased levels of hepatitis E virus antigens in the
hepatocytes of the liver.
During epidemic outbreaks of hepatitis E disease, examination
of the infected patient’s liver shows two general types of
morphological changes. A characteristic cholestatic pattern, glandular
modification of the parenchymal cells and notable bile stasis within the
canaliculi of the liver called cholestatic form.
Immune mediated reaction of the host results in the infiltration
of the liver cells with polymorphonuclear leucocytes and lymphocytes
which may be the cause for the liver injury and they have been found
to have suppressor or cytotoxic immunophenotype.
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A second type of histopathological pattern observed is similar to
the other forms of acute viral hepatitis which includes acidophilic
bodies’ formation and ballooning degeneration of the hepatocytes or
confluent hepatocyte necrosis in the liver 4,6.
PREGNANCY AND HEV
Pregnant women, particularly those in 2nd and 3rd trimester of
pregnancy are more frequently affected during hepatitis E outbreaks.
They have a worse outcome than other form of viral hepatitis.
It was proposed that severe fetal infections and fetal death may
produce toxins that overload circulation which causes severe maternal
disease27. During pregnancy there is increased sensitivity to hepatitis E
virus mediated endotoxins1 called Schwartzman-like phenomenon.
Hepatitis E virus infection are fatal due to hepatic and renal failure as
they precipitate pregnancy associated eclampsia with disseminated
intravascular coagulation28.
Following are the possible host factors that favor’s fulminant
hepatic failure to occur in hepatitis E infected pregnant women’s:
Immunological changes
Hormonal changes during pregnancy
Genetic and environmental factors
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IMMUNOLOGICAL CHANGES DURING PREGNANCY28
During the early weeks of gestation up to 20th weeks, T cells are
significantly reduced. It is a protective modulation of cell mediated
immunity (CMI) to sustain the highly antigenic fetus and the placenta
during pregnancy. Placenta are resistant to cell mediated damage as
they do not express MHC.
They express a unique HLA-G molecule which inactivates
Natural Killer cells by binding to its receptors CD16 and CD56. It also
produces indoleamine 2,3dioxygenase enzyme, inactivate and deplete
the aminoacid tryptophan, which supports T cell function and hence
suppresses CMI. Increase in cytokines such as TGF-β, IL-4 and IL-10
inhibits cell mediated immunity.
HORMONAL FACTORS IN PREGNANCY
Increased incidence of FHF may be associated with
hormonal changes. As the period of gestation progresses the hormones
like estrogen, progesterone and human chorionic gonadotropin also
increases. Estrogen causes shrinkage of thymus and deplete the number
of CD4 and CD8 cells. Progesterone blocks T cell development i.e.
they inhibit Th1 cell and promote Th2 cells by producing involution of
thymus more effectively than estrogen. It was also shown that there is
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increased level of T helper2 cytokines assuming this may cause liver
injury and have a role in increased severity of HEV infection in
pregnancy25.
PROBABLE MECHANISM OF FATAL FULMINANT
HEPATIC FAILURE IN PREGNANCY19
In addition to the above mentioned hormones, high levels of
steroid hormones are also appreciated during pregnancy. Through NF-
κB steroids mediate lymphocyte apoptosis and this physiological down
regulation helps to retain the fetus. In studies it was shown that the
activity of p65 component of NF-κB was decreased in peripheral blood
mononuclear cells as well as liver biopsy of pregnant women died of
fulminant hepatic failure. It was established that absence of p65 is
responsible for liver damage in fulminant hepatic failure associated in
hepatitis E infected mothers.
CLINICAL MANIFESTATION
Incubation period ranges from 2 to 8 wks for the clinical
manifestation of the disease. Wide spectrum of clinical manifestation
have been observed, from self-limiting, subclinical, acute hepatitis to
fulminant hepatitis in case of pregnant mothers but never proceeds to
chronicity.
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It is most commonly seen in the age group of 15 to 45. It is
mostly asymptomatic in children. 1% mortality of general population is
due to FHF.
SIGNS AND SYMPTOMS
PRE-ICTERIC OR FIRST PHASE
Influenza like symptoms
Abdominal pain
Tenderness
Nausea
Vomiting
ICTERIC OR SECOND PHASE
Jaundice
Dark urine
Viremia
Elevated liver enzymes
Antibody seroconversion
Clearing of the viruses
First phase or pre-icteric phase lasts for 1 to 10 days followed by
second or icteric phase persist for 15 to 40 days.
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OUTCOME OF HEV
Typically hepatitis E virus infection is self-limiting without
progression to the chronic illness. However hepatitis E infection is
more severe than hepatitis A. It causes fulminant hepatic failure in
pregnant women’s and can be fatal.
Fulminant form of hepatitis E infection occurs more frequently
in the third trimester of pregnancy with a mortality rate of 25%.
However, on the basis of clinical presentation hepatitis E cannot
be differentiated from other forms of viral hepatitis. In fact, not all
hepatitis E infections are clinically apparent.
Increased frequency of abortion, neonatal deaths and still births
are noted among pregnant mothers with hepatitis E infection4
Other complications are prolonged cholestatic hepatitis, acute
HEV superinfection in patients with cirrhosis, co-infection with other
hepatotropic viruses and autochthonous hepatitis E virus in developed
countries
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SEROEPIDEMIOLOGY
Hepatitis E cause waterborne epidemic disease with peak
clinical attack rate in young adults and high rate of fulminant hepatitis
in pregnancy. The earliest recorded outbreak of HEV occurred in the
year 1955 in Delhi, India, following heavy flooding of the river
Yamuna. Thereafter, many number of outbreaks and sporadic cases
have been documented in a wide variety of developing and tropical
regions, together with, India, Nepal, Pakistan, Myanmar, Indonesia,
china, the central Asian region of the former Soviet Union, Ethiopia,
Egypt, Algeria, Jordan, the Ivory Coast, Sudan, Chad, Somalia,
Ethiopia, and Mexico4,5.
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Sporadically occurring hepatitis in many of the regions have
been serologically confirmed as hepatitis E virus infection. In fact,
hepatitis E virus is one of the most common etiology of sporadic
hepatitis in the endemic regions.
Salient feature of hepatitis E is that it has age specific clinical
attack rate with its peak among young adults ranging from 15 to 40
years of age in developing countries1. Survey of sera collected from a
hepatitis E endemic area of India over a period of ten years,
documented that most hepatitis A infection occurred before five years
of age, whereas, hepatitis E virus infection occurred after sixteen years
of age. However, all age groups are affected with male preponderance
and mostly adults develop clinical evidence of hepatitis than children
during epidemics2,3.
In most hepatitis E endemic areas, antibodies have been
identified in 5% of children in the age group less than ten years when
compared to 10% to 40% in young adults >25 years of age4. Recent
study from India have reported >60% of children <5 years of age have
antibodies against hepatitis E virus4.
By Nargis et al, seroprevalence of anti-hepatitis E IgG in New
Delhi, India is 33.67% in asymptomatic healthy mothers2. Whereas in
Spain and Turkey prevalence it is 0.6-2 and 12.6 percent respectively2.
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Arankalle et al, seroprevalence of IgG in general population is
23.62%2. By Khuroo et al, it is 5% in asymptomatic in healthy
children2.
By Radhakrishnan et al, among 361 cases of acute viral hepatitis
17.3%(66) were positive for IgM29. By Singh et al 40% of pregnant
women were positive for IgM anti HEV antibody29. By Bista et al, out
of 19 jaundiced pregnant women 16 (84.2%) were positive for anti
HEV IgM antibody29.
Relatively high seroprevalence rate were reported in developed
countries like japan (4%-7%) and U.S (15%- 20% in blood donors)28.
The urban sewage samples from non-endemic areas like Spain, Greece,
France, Sweden, and U.S tested positive for hepatitis E virus
infection28, signifying that the healthy population of non-endemic areas
may also be exposed to other types of animal HEV strains that do not
develop any clinical manifestations.
Development of sensitive serological assay has permitted for
complete analysis of HEV seroprevalence and its distribution
worldwide. Unpredictably, the prevalence of anti HEV IgG in noted
endemic regions has been much lower than anticipated and the
occurrence of such anti HEV in non-endemic regions has been in much
higher levels.
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Molecular methodology to the epidemiology of hepatitis E virus
hold some promise. The moderately low level of hepatitis E in blood
and faeces restricts the practicality of hybridization without
amplification. RT-PCR has been useful for checking the outcomes of
serological test and for assessing the duration of infectivity of the
cases. Limitation to molecular epidemiological studies are due to fairly
short duration of faecal shedding and viremia. Its main significance is
identification of different types of hepatitis E virus genotypes and their
association to specific epidemics and environmental locations.
Furthermore, RT-PCR has been used to identify hepatitis E in sewage
and contaminated water.
RISK GROUP IN THE POPULATION7,16
1.People living in areas where community outbreaks of hepatitis E
infection occurs
2. People living in overcrowded refugee camps following disastrous
events
3. People travelling to hepatitis E endemic areas
4. People with chronic liver disease
5. People handling pigs, cows, sheep, goat and non-human primates
which may be infected with hepatitis E virus.
6. Travellers to the endemic areas
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DIAGNOSIS
Hepatitis E should be should be suspected in endemic areas
during outbreaks of water-borne hepatitis in people living in sub
optimal sanitary conditions. In developed nations hepatitis E should be
suspected in patients presenting with signs and symptoms of hepatitis
with history recently returned from endemic areas. Similar to the other
forms of viral hepatitis, serological tests play an important role in
establishing a definitive diagnosis of hepatitis E.
Specific test for anti HEV IgM and IgG antibodies are available.
IgM is the acute phase marker and IgG determines the exposure to
HEV. Detection of IgM is up to 90% during acute infection if the
suspected patient’s serum samples are collected between 1 and 4 weeks
after the onset of symptoms. During the first 4 weeks of infection after
the onset on disease, IgM reaches peak titer of 1:1000 to 1:10000 and
disappears within 3 months in 50% of the patients5. Between 2 and 4
weeks, IgG peaks in titer of 1:1000 to 1:100000 and thereafter
diminishes rapidly relatively5. According to Clayson et al., in the
infected people IgG antibodies against HEV persist for more than 14
years in 47% of the patients7.
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IMMUNOLOGICAL DIAGNOSIS
ENZYME IMMUNO ASSAY (EIA)7
IMMUNOFLUORESCENCE MICROSCOPY (IFE)
WESTERN BLOT
EIA is a highly sensitive and inexpensive and a practical method
for detection of antibodies against hepatitis E virus.
IgM- acute phase marker
IgG- measure exposure to hepatitis E
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Specific antibodies can be detected in either blood or serum.
Following are the antigenic domains found in the ORFs proteins.
1. ORF1 – 12 antigenic domains
2. ORF2 – 6 antigenic domains
3. ORF3 – 3 antigenic domains
Complete ORF3 and large segment of ORF2 or ORF3 C end
domain and recombinant proteins originating from the ORF2 are used
for detection of IgM and IgG antibodies of HEV. In the convalescent
stage of the disease course, ‘capsid-like’ or large ORF2 particles are
more effective in detection of anti HEV.
Synthetic peptide antigens are used to confirm enzyme immune
assay results and to exclude nonspecific reactions. Their use increase
the specificity of the reaction and helps to determine the genotype of
hepatitis E. Disadvantage of this peptide antigens is that it has low
sensitivity and not reliable in detection of antibodies in the
convalescent period7.
Four short recombinant proteins derived from 3’ end of ORF-2 with
42 amino acid and ORF-3 with 33 amino acid of Burmese (genotype –I
) and Mexican (genotype –II) are used by two Genelab EIA. 2
recombinant proteins obtained from the complete ORF3 with 123
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amino acid of the Burmese genotype I strain by Abbott –EIA7.
Sensitivity, specificity, positive predictive value and negative
predictive values of all three combination of EIA’s are 100%, 99.5%,
75% and 100% respectively7.
According to Mast et al, 12 different enzyme immune assay
showed a concordance from 41 to 94 percent in blood donors and 0 to
89% among reactive sera with mean 68 and 32 percent respectively7.
During acute HEV infection inflammation of liver or damage to
liver tissues can be assessed by elevated liver enzymes like
glutamyltranspeptidase (GGT) alanine aminotransferase (ALT)
IMMUNOFLUORESCENCE MICROSCOPY (IFE)
This is a semi-quantitative test measures the concentration of
anti HEV antibodies against hepatitis E virus. Fluorescein–conjugated
anti-HEV IgG to hepatitis E antigen in the liver tissue is blocked by
anti HEV antibodies.
IFE is expensive and laborious and hence not useful for routine
diagnosis.
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MOLECULAR DETECTION OF HEV
IMMUNE ELECTRON MICROSCOPY
NUCLEIC ACID AMPLIFICATION TEST
VIRAL ISOLATION
IMMUNE ELECTRON MICROSCOPY (IEM)17
Balayan et al., 1983 used IEM to detect virus like particles in the
clinical specimens. Antibodies to HEV derived from acute phase or
convalescent phase sera, precipitate the HEV particles. By rating the
antibody coating, concentration of the anti HEV antibody can be
determined semi-quantitatively.
For routine analysis, immune electron microscope (IEM) is not
suitable as its sensitivity and specificity of the assay is insufficient.
Moreover clinical samples contains less number of virus like particles
to be detected by IEM.
Molecular methods in diagnosis of hepatitis E have replaced
Immune electron microscopy as it is positive in only 10% of cases5.
NUCLEIC ACID AMPLIFICATION TEST
They can be used to detect HEV RNA either in
serum/blood or stool. These tests are of importance during the window
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period as the specific antibodies to HEV are not mounted to the
detectable levels, hence the serological test are found to be negative3.
Nested RT PCR and real time RT PCR are nucleic acid based
techniques is the method of choice for the specific detection of HEV
RNA in blood and faeces during the acute phase of infection. This
method is very advantageous in detecting divergent hepatitis E virus
strains in non-endemic countries where some assay fail to detect
serological response to hepatitis E. But the sensitivity of the test
depends on a proper match between the hepatitis E virus strain and the
PCR primers.
Conventional RT-PCR detects viral RNA, not only from sera
and faeces in humans and also detects from clinical samples like bone
marrow, plasma, serum, salivary gland, mesenteric lymph nodes,
inguinal lymph nodes, kidney, urine, liver and bile of domestic pigs
and other animals like wild boar, sika deer, mongoose, chickens and
also in contaminated water7.
VIRAL ISOLATION17
For viral characterization and diagnosis, establishment of a
practical cell culture that allow the multiplication of hepatitis E in vitro
is very critical. The human lung diploid cell culture system (2BS,
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PLC/PRF/5, A549,HepG2) and primary cell culture system from non-
human primates like chimpanzees, African green monkeys,
cynomolgus macaques and tamarins have been reported7,17.
But these cell culture medium cannot be used for virological and
biophysical studies of hepatitis E because they do not provide high-tire
of HEV in the culture medium and have reproducibility.
Toshinori Tanaka et al used Fecal suspension with 2.0 x 10-7 of
HEV copies ml-1 were used successfully in developing a cell culture
system with an HEV titre of up to 108 in PLC/PRF/5 cells 17.
TREATMENT
Treatment of hepatitis E virus is supportive and involves bed rest,
adequate hydration and electrolyte repletion. Almost all of them able to
clear the virus spontaneously. There is no specific therapy available in
altering the course of acute hepatitis E infection. Antivirals have not
been effectively established for the treatment of hepatitis E infection.
In acute severe form of infection, patients are treated with ribavirin for
21 days. Pilot studies in cell culture suggest that interferon alpha and
ribavirin may inhibit hepatitis E virus1.Though ribavirin is
contraindicated in pregnancy for its teratogenicity, the risk of untreated
hepatitis E infected mother and fetus are essentially high.
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PREVENTION OF HEPATITIS E VIRUS
Following are the most important means of prevention
o Good personal hygiene
o High quality public water supplies
o Proper disposal of sanitary waste and
o General food safety
RECOMMENDATION16:
1. Disease surveillance and outbreak detection
a. Enhance hepatitis E diagnosis and reporting in all acute
hepatitis cases particularly those that test negative for hepatitis A
and hepatitis B virus to enable epidemiological investigation and
out breaks
b. Use of molecular methods to determine the different
genotype prevalence in an area.
2. Food and water safety
a. Increased awareness among food handlers
b. Food surveillance programme for hepatitis E
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3. Public health education
a. Sea foods like shell fish, pork and pig offal should be cooked
completely before consumption
b. To take appropriate measures to prevent hepatitis E infection
when travelling to an endemic areas
4. Local study
To monitor hepatitis E prevalence and epidemiological changes
SWINE HEV
For the first time in the year 1997 by Meng et al, HEV from the
clinical samples of pigs in USA was identified and demonstrated.
Subsequently, other countries from all over the world with high
production of pork, hepatitis E virus strains have been detected. These
hepatitis E genotypes showed their association with genotype III and
genotype IV. Swine HEV strain is almost homologous with the human
hepatitis E from the same geographic location(Hsieh et al, Pina et al,
Wang et al, Huang et al, Yazaki et al)7,. The swine hepatitis E virus
shared more than 97% amino acid identity with human hepatitis E
genotype III16. Isolates of hepatitis E virus strains from Thailand and
Mexico has been classified as genotype III where human isolates of
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hepatitis E has been categorized as genotype I and II. In India human
HEV strains are designated as genotype I and swine as genotype IV7.
AVIAN HEV
In U.S., chickens suffered with Hepatitis-splenomegaly
syndrome from whom the novel HEV strain, the avian HEV was
isolated from the bile samples by Haqshenaset al7. Comparison of
avian HEV and BSLV (big liver and spleen disease virus) revealed
resemblance of about 80%. Sequenced genome segment of isolates of
avian HEV showed 50 to 60 percent similarity with human and swine
HEV strains7. Variation in the position of ORF was observed, ORF 3
does not shown overlapping with ORF-1 unlike classical hepatitis E
viral genome. According to Wang et al, and Haqshenas et al, it is not
clear that whether isolates of avian HEV has different V of hepatitis E
or it is another member of Herpevirus genus7. Later, phylogenetic
analysis and sequence comparison of avian HEV discovered that it is
most divergent of the hepatitis E virus strains and had 50% sequence
identity28. Newly, another new avirulent strain of avian HEV was
isolated from seemingly healthy chickens. It is assumed that the 2
avian HEV strains fit into presumed genotype V28.
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ANIMAL EXPERIMENTS
Several species of monkey and chimpanzees are susceptible to
hepatitis E virus infection. Most of our understanding of the
pathogenesis of hepatitis E infection is derived from the reliable non-
human experimental animal models like rhesus, cynomolgus
macaques, owl monkeys and tamarins.
Incubation period was 21 days after intravenous inoculation of
Hepatitis E virus into cynamolgus macaques. During the initial highly
replicative cycle, expression of HEV Ag appears approximately 7th day
post infection4,6. During 2 or 3 week after inoculation, HEV Ag has
been detected in feces, bile and hepatocyte cytoplasm due to excretion
of HEV into bile.
Antigenic expression of hepatitis E covers approximately
70%to90% of the hepatocytes and the quantity of viral antigen declines
with the onset of raise in liver enzymes and there was fecal excretion
of virus and viremia in the blood. Detectable antibodies to hepatitis E
virus appears just before the elevation of ALT(alanine
aminotransferase) and coincides with resolution of faecal virus
shedding, viremia in the blood and reduction in the viral antigen in the
liver and correspond to the presence of histopathogical changes in the
liver. In the last decade, a growing trend of hepatitis E notification has
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been observed. From 2001 to 2010, the yearly notification of hepatitis
E infection in the past decade has ranged from 26 to 117. In fact,
hepatitis E turn out to be the most common cause of viral hepatitis
reported in 2010. Hepatitis E  accounts  for  44.3%  of  all  viral
hepatitis  cases,  followed  by  27.7% of viral  hepatitis  B  and  24.2%
of viral  hepatitis  A
India is endemic for hepatitis E infection and it is the most
common cause of viral hepatitis in pregnancy with high mortality
during 3rd trimester following fulminant hepatic failure which may be
associated with the hormonal changes during the course of
pregnancy22.Hepatitis E virus gives a large global burden of sporadic
and epidemic hepatitis.
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MATERIALS AND METHODS
TYPE OF STUDY:
Prospective study.
STUDY PLACE:
This study was done in the Department of Microbiology, Stanley
Medical College and Hospital in association with Department of
Obstetrics and Gynecology, RSRM and Medical Gastroenterology,
Stanley Medical College and Hospital, Chennai.
PERIOD OF STUDY:
Jan 2014 – sept 2014
SAMPLE SIZE:
200
INCLUSION CRITERIA
All the asymptomatic pregnant mothers who were attending the
antenatal OPD and who were willing to provide written informed
consent were recruited for the study.
EXCLUSION CRITERIA
Antenatal mother with signs & symptoms of hepatitis.
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PATIENT SELECTION:
The study was conducted among the asymptomatic pregnant mothers
attending routine antenatal check-up in the Department of Obstetrics
and Gynaecology, RSRM and Medical Gastroenterology, at
Government Stanley Medical College and Hospital, Chennai for a
period of 9 months from Jan 2014 to Sept 2014.
Population group were from in and around Chennai.
The study was explained in detail to the pregnant mothers in their local
language and informed consent were obtained.
All asymptomatic antenatal mothers who were willing to give informed
consent irrespective of their gestational age were enrolled in the study.
No samples were repeated from the same patients.
200 asymptomatic pregnant mothers were selected for this study.
Blood samples were collected and serum was separated from them to
detect the presence of IgM and IgG antibodies to HEV and to detect
viral RNA by PCR.
ETHICAL CONSIDERATION:
Ethical and research clearance was obtained from the ethical
committee Stanley Medical College and Hospital. Permission to
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conduct the study was sought from the respective hospital authorities.
Informed consent was obtained in the local language of the patient
before enrolment into the study.
Statistical analysis:
The collected data was analysed with SPSS 16.0 version. To
describe about the data descriptive statistics frequency analysis,
percentage analysis, cross tabulation were used for categorical
variables and the mean and S.D were used. To find the significance in
categorical data Chi-Square test was used. In all the above statistical
tools the probability value .05 was considered as significant level.
DATA COLLECTION:
Details were obtained directly from the patients with the help of
a questionnaire which dealt with information regarding
sociodemographic data such as age, residential address, educational
status, profession, socioeconomic status, source of drinking water and
type of toilet facility to analyse various factors that contribute for the
prevalence of HEV infection in pregnant mothers in the particular
geographic area.
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SAMPLE COLLECTION:
Under aseptic precaution around 5 ml of blood sample was
collected from each patients by venipuncture at the cubital fossa, by
using 23G needle. Blood was dispensed into a sterile test tube without
anticoagulant. Samples were transported immediately to the
Microbiology lab. The blood was centrifuged at 2500 rpm and the
serum was separated. Samples were duplicated and stored in a storage
vials containing 50µl of EDTA at -80°C deep freezer.
One set of serum samples were used for doing indirect ELISA
(Enzyme Linked Immunosorbent Assay) to detect both IgG and IgM
antibodies against Hepatitis E virus. Other set of samples were used for
HEV-RNA detection using Seminested Reverse Transcriptase PCR
(HELINI biomolecules).
ELISA (Enzyme Linked Immunosorbant Assay)
ELISA was done with a commercial kit
1. DSI-EIA-ANTI-HEV-IgM-KIT
2. DSI-EIA-ANTI-HEV-IgG-KIT
This test was intended for the screening of serum IgM and IgG
antibodies against HEV. The test was performed according to the
instructions provided in the kit literature.
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PRINCIPLE OF THE TEST:
TYPE OF ELISA: INDIRECT ELISA
Diluted test serum samples when added to the HEV antigens coated
strips, if specific antibodies to the antigen are present in the serum,
they get bound to each other in the wells during the incubation period.
Unbound antibodies were removed during washing. When freshly
prepared enzyme conjugate was added, it specifically binds to the
antigen antibody complex that had formed during the first incubation.
Unbound conjugate were removed during washing. To this a
chromogen substrate was added. The peroxidase enzyme present in
substrate catalyse the reaction that consumes peroxide and turned the
chromogen from clear to blue. Addition of stop solution end the
reaction and turned the blue colour to a bright yellow colour. The
reaction was read with an ELISA reader.
MATERIALS AND EQUIPMENTS REQUIRED
1. Purified water
2. Pipettes to measure and dispense 10, 50, 90, 100
3. Pipette tips
4. Incubator at 37.0±1.0 C
5. Automated microplate washer
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6. Microplate reader equipped with 450nm
7. Disposable gloves
REAGENTS
1. 96 microtitre wells coated with HEV antigens
2. Wash buffer
3. Sample diluent
4. Enzyme conjugate and diluent
5. TMB substrate and substrate buffer
6. Stop solution
7. Positive control (inactivated)
8. Negative control(inactivated)
HANDLING OF SPECIMENS
Plasma stored at -80°C was thawed for few minutes at 40°C to
avoid fibrin precipitation.
AUTOMATIC MICROPLATE WASHER:
Automatic ELISA plate washer was set up appropriately i.e. 380-400µl
working washing solution into each wells and soak time at least 40
seconds and aspirate.
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PREPARATION OF THE REAGENTS
HEV –Ag COATED STRIPS
The foil bag was opened and the strips were removed and placed
in the microtitre plate. The strips were numbered and the wells were
assigned with the respective samples with the help of a data sheet.
Before initiating the assay all the strips were washed 2 times with the
automatic microplate washer, as instructed in the manual.
PREPARATION OF WASH BUFFFER
To 50ml of washing buffer (concentrated 25 fold) 1200ml of
distilled water (1:25 ratio) was added and mixed thoroughly according
to the manual.
PREPARATION OF THE WORKING CONJUGATE
Working conjugate was prepared just before the test procedure.
To 0.65ml of conjugate (concentrated 21 fold) 13ml of conjugate
diluent (1:20 ratio) was added and thoroughly mixed until diluted.
Intensive mixing was avoided.
PREPARATION OF THE SUBSTRATE MIXTURE
The substrate mixture was prepared just before use. To 0.65ml
of TMB (concentrated 21 fold) 13ml of substrate buffer (1:20 ratio)
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was added and mixed thoroughly until diluted. This step was done after
darkening the room as it was sensitive to light.
DS-EIA-ANTI-M ASSAY PROCEDURE:
BEFORE ASSAY
The coated strips was washed with working washing solution 2
times before the procedure. The microtitre plate was tapped over tissue
paper and was made sure thatfluid or bubbles were not left inside the
wells as they may adversely affect the assay precision. Data sheet are
made ready for the controls and for the samples.
1. 100µl of Positive control was added into one well and Negative
control was added in 2 wells.
2. 90µl of sample diluent and 10µl of test serum were added in the
rest of the wells.
3. The plate was covered by a lid protective film.
4. The plate was incubate for 30 minutes at 37±1°C in the
incubator.
5. The contents was removed by washing the plate for 4 times.
6. 100µl of freshly prepared working solution of conjugate was
then added into each wells.
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7. The plate was covered by a lid protective film.
8. The plate was incubate for 30 minutes at 37±1°C in the
incubator.
9. The contents was removed by washing the plate for 4 times.
10.100µl of freshly prepared substrate mixture was added into each
wells.
11.The plate was kept in a dark place for 20 minutes at 18-24°C
12.150µl of stopping reagent was added to all the reacting wells.
13.Optical density at 450/620 nm using microplate reader was used
to read the result immediately after adding stop solution.
Validation of the test was confirmed by the following:
Positive control > 0.6 and Negative control < 0.2
CUT – OFF = AVERAGE OF NEGATIVE CONTROL + 0.200
(coefficient defined by manufacturer during statistical processing for
each lot)
INTERPRETATION OF RESULTS
Sample was considered NEGATIVE if OD < CUT – OFF
Sample was considered POSITIVE if OD ≥ CUT – OFF
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PREPARATION OF THE REAGENTS FOR IgG ANTI HEV
HEV –Ag COATED STRIPS
The foil bag was opened and the strips were removed and placed
in the microtitre plate. The strips were numbered and the wells were
assigned with the respective samples with the help of a data sheet.
Before initiating the assay all the strips were washed 2 times with the
automatic microplate washer, as instructed in the manual.
PREPARATION OF WASH BUFFFER
To 50ml of washing buffer (concentrated 25 fold), 1200ml of
distilled water (1:25 ratio), was added and mixed thoroughly according
to the manual.
PREPARATION OF THE WORKING CONJUGATE
Working conjugate was prepared just before the test procedure.
To 0.65ml of conjugate (concentrated 21 fold), 13ml of conjugate
diluent (1:20 ratio) was added and thoroughly mixed until diluted
avoiding foaming. Intensive mixing was avoided.
PREPARATION OF THE SUBSTRATE MIXTURE
The substrate mixture was prepared just before use. To 0.65ml
of TMB (concentrated 21 fold), 13ml of substrate buffer (1:20 ratio)
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was added and mixed thoroughly until diluted. This step was done after
darkening the room as it was sensitive to light.
DS-EIA-ANTI-M ASSAY PROCEDURE:
BEFORE ASSAY
The coated strips was washed with working washing solution 2
times before the procedure. The microtitre plate was tapped over tissue
paper and was made sure that no fluid or bubbles are left inside the
wells as they may adversely affect the assay precision. Data sheet are
made ready for the controls and for the samples.
1. 100µl of Positive control was added into one well and
Negative control was added in 2 wells.
2. 90µl of sample diluent and 10µl of test serum were added in the
rest of the wells.
3. The plate was covered by a lid protective film.
4. The plate was incubate for 30 minutes at 37±1°C in the
incubator.
5. The contents was removed by washing the plate for 4 times.
6. 100µl of freshly prepared working solution of conjugate was
then added into each wells.
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7. The plate was covered by a lid protective film.
8. The plate was incubate for 30 minutes at 37±1°C in the
incubator.
9. The contents was removed by washing the plate for 4 times.
10.100µl of freshly prepared substrate mixture was added into each
wells.
11.The plate was kept in a dark place for 20 minutes at 18-24°C
12.150µl of stopping reagent was added to all the reacting wells.
13.Optical density at 450/620 nm using microplate reader was used
to read the result immediately after adding stop solution.
Validation of the test was confirmed by the following:
Positive control > 0.6 and Negative control < 0.2
CUT – OFF = AVERAGE OF NEGATIVE CONTROL + 0.200
(coefficient defined by manufacturer during statistical processing for
each lot)
INTERPRETATION OF RESULTS
Sample was considered NEGATIVE if OD < CUT – OFF
Sample was considered POSITIVE if OD ≥ CUT – OFF
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NUCLEIC ACID AMPLIFICATION TEST BY REVERSE
TRANSCRIPTASE PCR
RNA EXTRACTION:
PRINCIPLE:
Cells are lysed during a short incubation with chaotropic
salt, which immediately inactivate all nucleases. Cellular nucleic acids
bind selectively to special glass fibers pre-packed in the purification
filter tubes. Bound nucleic acids are purified in a series of rapid ‘wash
and spin’ steps to remove contaminating cellular components.
A special inhibitor removal buffer has been included
which removes inhibitors from the preparation. Finally elution buffer
releases the nucleic acids from the glass fibre. This simple method
eliminates the need for the organic solvent extractions and nucleic acid
precipitation, allowing for rapid purification of many samples
simultaneously.
MATERIALS REQUIRED
1. Micro pipette variable volume 0.5-10µl , 10-100µl and
100-1000µl
2. Sterile pipette tips with aerosol barrier 0.5-10µl, 2-
20µl, 10-100µl and 100-1000µl
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3. Disposable powder free gloves
4. Pure fast spin column
5. Vortex mixer
6. water bath
7. Centrifuge with rotor for 1.5 ml reaction tube
8. 1.5ml/ 2ml centrifuge tubes
SAMPLE: serum samples
Before use all samples and reagents were thawed completely, mixed
and centrifuged briefly.
PROCEDURE:
1. The following reagents were added to a nuclease free 1.5ml
centrifuge tube:
a. 200µl of lysis buffer
b. 5µl of carrier RNA
c. 200µl of plasma
d. 20µl of proteinase K
2. Centrifuge tube was mixed immediately by inverting it.
3. The tube was incubate at 56° C for 15min.
4. After taking the tube from incubator 300µl of 100% ethanol was
added and mixed by a vortex for 30 seconds.
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5. Then the tube was centrifuged for few seconds to bring down
drops to bottom of the tube.
6. Entire sample was then transferred into the pure-fast spin
column.
7. The pure fast spin column was centrifuge at 12000 rpm for 1
min.
8. The flow-through was discarded and the column was placed
back into the same collection tube.
9. To this 500µl of 70% ethanol was added to the pure-fast spin
column.
10.The pure fast spin column was centrifuge at 12000 rpm for 1
min.
11.The flow-through was discarded and the column was placed
back into the same collection tube.
12. Empty spin column was attached with collection tube and
centrifuged at 12000 rpm for an additional 2 min essentially to
avoid residual ethanol.
13. After that the collection tube was discarded.
14. The pure fast spin column was transferred to a fresh 1.5ml
centrifuge tube
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15. To this, 50µl of elution buffer was added to the Centre of pure
fast spin column membrane and incubate for 2 min at room
temperature.
16.The pure fast spin column and the centrifuge tube was
centrifuged at 12000rpm for 1 min and the pure fast spin column
was then discarded.
17. Now the centrifuge tube containing the eluted nucleic acid was
stored at -80°C for PCR analysis.
SEMI NESTED REVERSE TRANSCRIPTASE PCR REACTION
MATERIALS REQUIRED:
 0.2ml PCR tubes
 Micro pipettes variable volume
 Sterile pipette tips with aerosol barrier
 Vortex mixer
 Centrifuge with rotor for 1.5ml reaction tubes
SAMPLE: extracted viral nucleic acid
All precautions to avoid PCR contamination were undertaken.
Before use all the reagents were thawed completely, mixed and
centrifuged briefly.
Semi nested Reverse transcriptase PCR was done in two steps
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STEP1: c DNA synthesis
Master mix was prepared by the following reagents provided in
the kit for one sample in a 1.5ml micro centrifuge tube.
 RT Mix = 6µl
 cDNA primer mix= 4 µl
 enzyme mix=0.5 µl
1. All of the above was spun down at 1000rpmfor 30 seconds.
2. 10.5 µl of the master mix was taken and 9.5 µl of the extracted viral
nucleic acid was added to each PCR reaction tube.
3. Then it was incubated in a thermocyclerat 42°C for 45 minutes.
4. This step was critical to inactivate the reverse transcriptase
STEP2: PCR reaction set up
Master mix was prepared by the following reagents provided in
the kit for one sample in a 1.5ml micro centrifuge tube.
 PCR master mix = 10µl
 Primer mix          = 10 µl
 Water                  = 3 µl
 c DNA                 = 2 µl
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PRIMER PREPARATION
The above reagents were mixed together and spun down at
1000rpm for 30 seconds to avoid loss of DNA pellets.
POSITVE CONTROL
23µl of the primer mix and 5µl of positive control in one PCR
reaction tubes was taken.
NEGATIVE CONTROL
23µl of the primer mix and 2µl of nuclease free water in one
PCR reaction tubes was taken.
SETTING UP OF PCR REACTION:
1. 23µl of the primer mix and 2 µl of the STEP-1 product in each
PCR reaction tubes.
2. Positive control and negative control were also included.
3. The reaction vials were incubated in a thermocycler
 Initial denaturation: 95°C for 5 min
 35 cycles of
-Denaturation at 95°C – 30sec
-Annealing at 60°C – 30sec
-Extension 72°C - 30sec
 Final extension at 72°C – 5min
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The primer sequence of the HEV targeted is
Forward:5’-GGAGCCATCACCTATGCCTTATGT-3'
Reverse Primer: 5'-ACGGGAGCAGCAAAAGGCTTG-3'
ANALYSIS BY GEL ELECTROPHORESIS
PREPARATION OF AGAROSE GEL
2% agarose gel was prepared by adding two grams of agarose powder
to 100 ml of electrophoresis buffer, then heated in a microwave oven
for 2 min, mixed until the agarose was evenly dissolved. After cooling
to about 60 °C 5 µl of ethidium bromide was added to 100 ml of the
gel to enable visualization of DNA after electrophoresis. Ethidium
bromide being carcinogen being handled with precaution.
A well-formed COMB/template was placed across the end of the
casting tray which was covered with a cellophane tape in its edges and
the freshly prepared gel was poured into the casting tray which act as a
mold. This was let to solidify at room temperature.
PREPARATION OF ELECTROPHORETIC BUFFER
To one litre of distilled water 20ml of Electrophoresis (TAE-
Tris Acetic acid –EDTA) buffer was added and freshly prepared. GEL
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GEL ELECTROPHORESIS
Electrophoresisbuffer was poured into the electrophoresis
chamber. After the gel has hardened enough, the gel was gently placed
on the electrophoresis tank and was made sure that the gel was
completely immersed in the solution and comb was removed carefully
from the gel.
10µl of DNA ladder, sample, negative control and positive
controls and were loaded into the gel wells using micropipette.
Electrical leads were connected to the electrophoresis tank. And
the current was supplied with a voltage 50-100V so that negatively
charged DNA migrate from cathode to anode. Gel running time was
approximately the time taken by the gel loading dye to cover three
fourth of distance in the gel.
After the gel electrophoresis, PCR products were observed using
UV transilluminator.
INFERENCE:
Ladder and positive control were formed appropriately.
No amplicons of size 200bp was seen.
Hence, no viral RNA was detected
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OBSERVATION AND RESULTS
Two hundred asymptomatic pregnant women attending routine
antenatal clinic in a tertiary care hospital, were included in the
Prospective study. Blood samples were collected and serum were
separated by centrifuging at 2500 rpm. All the serum samples were
stored in two sets to detect IgM, IgG antibodies against hepatitis E
virus and to detect HEV RNA by seminested PCR in the department of
Microbiology from January 2014 to September 2014. The results were
analysed as follows.
TABLE-1: AGE DISTRIBUTION
Trimester Age (n= 200)
16-20 21-25 26-30 31-35 TOTAL
1st Trimester 4 14 7 1 26
2nd Trimester 15 34 31 7 87
3rd Trimester 12 44 24 7 87
Total 31 92 62 15 200
% 15.5% 46.0% 31.0% 7.5% 100%
P Value 0.733
Mean Age 24.55
Std. Deviation 3.838
Commonest age group was between 21-25 years of age.
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TABLE 2: GRAVIDA
Trimester
Gravida
Primi 2nd Gravida 3rd Or Multi
Gravida
Total
1st Trimester 11 9 6 26
2nd Trimester 44 31 12 87
3rd Trimester 43 31 13 87
Total 98 71 31 200
% 49% 35.5% 15.5% 100%
P value 0.838
Df 4
Majority of the pregnant women were Primigravida (49%).
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TABLE: 3. EDUCATIONAL STATUS
Trimester
Educational Status
Illiterate Primary
School
Middle
School
High
School
Diploma Graduate Total
1st
Trimester
3 1 12 4 2 4 26
2nd
Trimester
11 13 33 20 1 9 87
3rd
Trimester
12 8 40 13 0 14 87
Total 26 22 85 37 3 27 200
% 13.0% 11.0% 42.5% 18.5% 1.5% 13.5% 100%
P Value O.156
Df 10
Most of the pregnant women have studied up to middle school (42.5%)
followed by high school (18.5%)
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TABLE: 4. SOCIOECONOMIC STATUS AND OCCUPATION
Trimester Socio Economic Status Occupation
Lower Upper
Lower
Lower
Middle
Upper
Middle
Total Working
Outdoor
Indoor
House
work Total
1st
Trimester
1 3 12 10 26 6 20 26
2nd
Trimester
- 27 31 29 87 7 80 87
3rd
Trimester
1 18 40 28 87 5 82 87
Total 2 48 83 67 200 18 182 200
% 1.0% 24.0% 41.5% 33.5% 100% 9.0% 91.0% 100%
P Value 0.211 0.023
Df 6 2
Majority of the pregnant women was in the lower middle class (41.5%)
and 91.0% of them were not working
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TABLE: 5.OVERCROWDING AND FOOD HABIT
Trimester Over Crowding Food Habit
Yes No Veg Non-Veg
1st Trimester 6 20 4 22
2nd Trimester 29 58 5 82
3rd Trimester 26 61 5 82
Total 61 139 14 186
% 30.5% 69.5% 7.0% 93.0%
P Value 0.6 0.199
Df 2 2
30.5% of the pregnant women resides in an overcrowded house and
93.0% of them were following non-veg diet.
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TABLE: 6. DRINKING WATER AND USE OF BOILED
WATER
Majority (49.5%) of the pregnant women used municipal water
available at their home and 75.5% of them did not used boiled water
1st
Trimester
2nd
Trimester
3rd
Trimester
Total %
Source Of Drinking Water
Aqua 1 0 1 2 1.0
Can 2 5 8 15 7.5
Lorry 1 17 17 35 17.5
Muni 14 48 37 99 49.5
Pump 6 12 13 31 15.5
Sump 2 2 4 8 4.0
Tap
Out
0 2 7 9 4.5
Well 0 1 0 1 0.5
Total 26 87 87 200 100%
P
Value
0. 258
Df 14
Use of boiled water
Yes 6 22 21 49 24.5
No 20 65 66 151 75.5
P
value
0.064
Df 2
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TABLE: 7. TOILET FACILITY AND USE OF SOAP FOR
HAND WASHING
Trimester
Toilet Facility Use Of Soap
Western Indian Common NoToilet Total Yes No
1st
Trimester
4 13 6 3 26 16 10
2nd
Trimester
1 50 21 15 87 56 31
3rd
Trimester
8 45 11 23 87 62 25
Total 13 108 38 41 200 134 66
% 6.5% 54.0% 19.0% 20.5% 100% 67.0% 33.0%
P Value 0.024 0.512
Df 6 2
Common toilet- Indian type
54.0% of pregnant women commonly used Indian toilet
20.5% of them had no toilet facility and used open field for defecation.
Majority of them were using soap for hand washing ie., 67%
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TABLE: 8. PROBABLE RISK FACTORS
Clinical Data 1st
Trimester
N=26
2nd
Trimester
N=87
3rd
Trimester
N=87
Total
N=200
H/O Blood
Transfusion
- - 10 11.5% 6 6.9% 16 8%
H/O jaundice
In The Patient
4 15.4% 15 17.2% 11 12.6% 30 15%
H/O Family
Of jaundice
2 7.7% 3 3.4% 2 2.3% 7 3.5%
H/O blood transfusion was more commonly seen in the 2nd trimester of
pregnancy
Both H/O jaundice and family H/O jaundice was present in pregnant
women in all three trimester
Above probable risk factors were statistically not significant.
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TABLE: 9. BLOOD GROUPS
Majority of the pregnant women had O+ blood group (46.0%)
followed by 22.5% of B+ women. Other blood groups were in the
range of 1% to 17 %.
Blood
Group
Trimester Total %
1ST 2ND 3RD
A- 0 1 1 2 1.0%
A+ 7 8 20 35 17.5%
AB+ 2 6 6 14 7.0%
B- 0 4 1 5 2.5%
B+ 5 20 20 45 22.5%
O- 1 3 3 7 3.5%
O+ 11 45 36 92 46.0%
Total 26 87 87 200 100%
P value 0.561
Df 12
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TABLE: 10. TIMESTER AND RESULTS OF ELISA AND
REVERSE TRANSCRIPTASE PCR
Trimester ELISA RT-PCR
Only
IgM +
n =5
Only IgG
+
n = 11
Both IgM+ &
IgG+
n = 7
HEV-
RNA
1st Trimester 0 1 3 -
2nd Trimester 3 5 2 -
3rd Trimester 2 5 2 -
Total 5 11 7 -
% 2.5% 5.5% 3.5% -
Over all IgM+ (5 + 7 = 12) ------- 6%
Over all IgG+ (11 + 7 = 18) ------- 9%
No cases were found to be positive for HEV-RNA by Reverse
transcriptase-PCR.
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TABLE: 11 AGE AND HEV POSITIVITY
Majority of the positive results of ELISA were seen in the age group
26-30.
Age Only
IgM+
% Only
IgG+
% Both
IgM+IgG+
RT-PCR
HEV-
RNA
16- 20 1 20.0% - - - -
21-25 - - 3 27.3% 4 -
26-30 4 80.0% 7 63.6% 3 -
31-35 - - 1 9.1% - -
Total 5 100% 11 100% 7 -
P
value
is 0.079 0.081 0.533
df 3 3 3
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TABLE: 12. GRAVIDA AND HEV POSITIVITY
Number Of
Pregnancy
ELISA RT-
PCR
IgM+ IgG+ Both
IgM+& IgG+
HEV-
RNA
Primi 1 20% 3 27.3% 3 42.9% -
2nd Gravida 3 60% 6 54.5% 3 42.9% -
3rd Or
Multi Gravida
1 20% 2 18.2% 1 14.3% -
Total 5 100% 11 100% 7 100% -
Seropositivity were more commonly seen the 2nd gravida.
HEV positivity cases were equal equally distributed between
primigravida and multigravida.
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TABLE: 13. EDUCATIONAL STATUS AND HEV POSITIVITY
Majority of the IgM and IgG positive cases were in the middle school
(57.1%) followed by primary school (42.0%).
Educational
Status
ELISA RT-
PCR
Only
IgM
+
% Only
IgG+
% Both
IgM+
IgG+
% HEV
RNA
Illiterate - - 1 9.1% - - -
Primary
School
1 20% 3 27.3% 3 42.0% -
Middle
School
3 60% 3 27.3% 4 57.1% -
High
School
1 20% - - - - -
Diploma - - - - - - -
Graduate - - 4 36.4% - - -
Total 5 100% 11 100% 7 100% -
P Value 0.822 0.064 0.064 -
Df 5 5 5 -
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TABLE: 14. SOCIOECONOMIC STATUS, OCCUPATION AND
HEV POSITIVITY
Socioeconomi
c Status
ELISA PCR
Only IgM+ Only IgG+ Both IgM+IgG+ HEV-
RNA
Socio Economic Status
Lower - - - - -
Upper Lower 2 40% 5 45.5% 4 57.1% -
Lower Middle 2 40% 3 27.3% 3 42.9% -
Upper Middle 1 20% 3 27.3% - - -
Total 5 100% 11 100% 7 100% -
P Value 0.880 3.051 5.826
Df 3 3 3
Occupation
Working - - 2 18.2% - -
Indoor
Housework
5 100% 9 81.8% 7 100% -
Total 100% 100% 11 100% 7 100% -
P Value 0.507 1.198 0.717
Df 1 1 1
Most of the HEV positivity were seen in the upper lower (57.1%) and
lower middle class (42.9%). All seropositive cases were seen in the
indoor housework group
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TABLE: 15. OVERCROWDING AND FOOD HABIT WITH
HEV POSITIVITY
Overcrowding and pregnant women having non-vegetarian diet were
seen to have most of the positive cases.
Over
Crowding
ELISA PCR
HEV
RNA
Only IgM+ Only IgG+ Both
IgM+ IgG+
Yes 3 60% 3 27.3% 5 51.4% -
No 2 40% 8 72.7% 2 28.4% -
Total 5 100% 11 100% 7 100% -
P Value 0.147 0.002 0.017
Df 1 1 1
Food Habit
Veg - - 1 9.1% 1 14.3% -
Non-Veg 5 100% 10 90.9% 6 85.7% -
Total 5 100% 11 100% 7 100% -
P Value 0.534 0.349 0.460
Df 1 1 1
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TABLE: 16. SOURCE OF DRINKING WATER AND USE OF
BOILED WATER WITH HEV POSITIVITY
Most of the positive cases were found in the people drinking
pump water and majority were not using boiled water.
Source of water ELISA RT-PCR
Only IgM+ Only IgG+ Both IgM+
IgG+
HEVRNA
Drinking water facility
Municipal
waterInside House
2 40% 5 45.5% 1 14.3% -
Municipal Water
CommonTap
- - - - -
Municipal Water
From Lorry
- - 1 9.1% 1 14.3% -
Municipal Water
Can Water And
1 20% - 1 14.3% -
Aqua guard Or
Purified Water
- - - -
Pump 2 40% 5 45.5% 4 57.1% -
Sump - -
Well -
Total 5 100% - 100% 7 100% -
P Value 0.714 0.233 0.132
Df 7 7 7
Use Of Boiled Water
Yes 2 40% 2 18.2% 1 14.3% -
No 3 60% 9 81.8% 6 85.7% -
Total 5 100% 11 100% 7 100% -
P Value 0.414 0.616 0.522
Df 1 1 1
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TABLE: 17.TOILET FACILITY AND USE OF SOAP WITH
HEV POSITIVITY
Toilet
Facility
ELISA PCR
HEV-
RNA
IgM+ IgG+ Both
IgM+ &
IgG+
Western - - 0 - 0 0 -
Indian 3 60% 3 27.3% 0 0 -
Common 2 40% 6 54.5% 4 57.1% -
No Toilet 0 - 2 18.2% 3 42.9% -
Total 5 100% 11 100% 7 100% -
P Value 0.456 0.018 0.008 -
Df 3 3 3 -
Use Of Soap For Hand Washing
Yes 1 20% 2 18.2% 0 0 -
No 4 80% 9 81.8% 7 100% -
P Value 0.024 0.000 0.000 -
Df 1 1 1 -
HEV Positivity were more commonly seen in pregnant women
using Indian type common toilets (57.1%) and without toilet facility
(47.9%)
Use of soap and HEV positivity were significantly associated
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TABLE:18. PROBABALE RISK FACTORS
AND HEV POSITIVITY
No significance was found between H/O blood transfusion,
H/O jaundice and family H/O jaundice and HEV positivity.
Clinical Data Only
IgM+
Only
IgG+
Both
IgM+
IgG+
HEV-
RNA
H/O Blood
Transfusion
2 - - -
H/O Hepatitis
In The Patient
1 - 2 -
H/O Family
Hepatitis
- - - -
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TABLE: 19. BLOOD GROUPS AND HEV POSITIVITY
Blood
Group
ELISA Total PCR
HEV
RNA
Only IgM+ Only IgG+ Both
IgM+ IgG+
A+ 2 2 - 4 -
B+ - 2 - 2 -
B- - - 1 1 -
AB+ - 2 1 3 -
O+ 2 5 4 11 -
0- - - - -
HEV positivity and blood group were not associated
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DISCUSSION
Earlier to the development of appropriate laboratory assays,
clinical hepatitis E virus infection was considered by the exclusion of
hepatitis A virus and hepatitis B virus (hence the designated as
NANB). Original methods for the detection of HEV infection involved
immune electron microscopy of stool or bile samples and fluorescent
antibody blocking technique to detect anti-HEV from serum samples
and liver sections of the patient. Both of these methods had very
limited sensitivity for the detection of hepatitis E virus both in acute
and remote infections and also expensive and laborious hence not
useful for routine diagnosis.
Enzyme Linked Immunosorbent Assay (ELISA) is the
serological test available for antibody detection of both anti HEV IgM
and IgG of hepatitis E virus infection. It is highly sensitive,
costeffective and a practical method for detection of HEV antibodies
Reverse Transcriptase PCR is a nucleic acid amplification based
technique. It is the method of choice for the specific detection of HEV
RNA in blood and faeces. The test is of importance during the window
period as the specific antibodies to HEV are not mounted to the
detectable levels, hence the serological test are found to be negative3.
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The population included in this study were asymptomatic
pregnant women who comes for routine antenatal check-up in a tertiary
care hospital. All patients were from different areas in and around
Chennai.
Sera of all the enrolled patients were analysed for the presence
of anti-HEV IgM and IgG antibody against hepatitis E virus by a
commercially available Enzyme Linked Immunosorbent Assay (DSI-
EIA-ANTI-HEV-M; DSI-EIA-ANTI-HEV-G) and HEV RNA was
detected by semi nested Reverse transcriptase PCR (HELINI
BIOMOLECULES).
AGE DISTRIBUTION (TABLE:1)
The study group included in asymptomatic pregnant mothers
were aged 16-35 years with the mean age of 24.55 years. According to
the study carried out by Shams et al, out of 65 pregnant women, the
mean age was 25 years60 and HEV seroprevalence seemed to be high
among 21-25 years of age (Andrew A Agjei et al)23. In the present
study, majority of the cases were in the age group of 21 to 25 (46%)
followed by 62(31%) cases in the age group 26 to 30 years.
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GRAVIDA (TABLE: 2)
Among 200 asymptomatic pregnant patients, 98 (49%) were
primigravida, 71 (35.5%) of them were 2nd gravida and 31 (15.5%)
were 3rd or multi gravida. Compared to primigravida, 2nd and multi
gravida were less in number. Most of them were in their second and
third trimester of pregnancy. According to Shams et al, HEV affects
more commonly the Primigravida and in the last trimester of
pregnancy60. According to MojtabaRasti et al, there was a significant
diference between seropositvity and different trimester of pregnancy
and most of the positive were occurred in the third trimester of
pregnancy61. According to Nargis Begum et al mean period of
gestation was 19.06 ±2.25 wk with a range of 16-24 wk2.
SOCIOECONOMIC STATUS AND OCCUPATION (TABLE:4)
In this study according to the Kuppuswamy’s criteria, following
were the distribution of socioeconomic status:
Lower class - 2 (1.0%)
Upper Lower class - 48 (24.0%)
Lower Middle class - 83 (41.5%)
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Upper Middle class - 67 (33.5%)
Majority of them were in the lower middle class. According to
Nargis begum et al lower socioeconomic status is the only main risk
factor associated with HEV IgG antibody2.
About 182 (91.0%) of them were indulged in indoor house work
and only 18 (9.0%) were outdoor working. This results were consistent
with the study done by Alain B. Labrique et al 56in which > 89% of the
women reported their occupation as indoor housework.
OVER CROWDING AND FOOD HABIT (TABLE: 5)
According to Bronfman’c criteria for assessing overcrowding
55(i.e., more than 3.5 person per living room), about 61 (30.5%) of the
pregnant women resides in an overcrowded house. Majority of them
were in the 2nd and 3rd trimester of pregnancy. According to Cosme et
al hepatits E sero prevalence was significantly associated with
overcrowding55.
Asymptomatic pregnant women 186 (93%) of the pregnant
women were following non-vegetarian diet whereas only 14 (7.0%) of
them were vegetarian. Rakesh et al4 has shown similar results as that of
our present study.
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DRINKING WATER AND USE OF BOILED WATER (TABLE:
6)
99 (49.5%) of the pregnant were using municipal water which
was available inside their home when compared to 9 (4.5%) of
pregnant women who get water from a common tap in the street. 35
(17.5%) of them get municipal water through lorry transportation. 15
(7.5%) and 2 (1%) of them use can water and purified water (using
aqua guard purifier) in addition to municipal water respectively.
According to Zimaity et al, patients residing in homes that were not
connected to a municipal source for drinking water appeared to have
increased risk for HEV infection 58.
49 (24.5%) of the pregnant women were using boiled water
whereas majority ie., 151 (75.5%) of them used water without boiling.
Cosmeet al55 studied that there was an association with use of boiled
water and HEV infectivity.
TOILET FACILITY AND USE OF SOAP (TABLE: 7)
108 (54.0%) of the pregnant women commonly used Indian
toilet. 38 (19.0%) and 13 (6.5%) of them were using common Indian
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toilet and western toilet respectively.41 (20.5%) of them had no toilet
facility and were using open field for defecation.
According to Surajudeen et al type of toilet facility was
significantly associated with HEV seroprevalence and found to be
more common among people who used open field for deafecation59.
Majority of them were using soap for hand washing i.e., 134
(67%) and remaining 66 (33%) did not have the habit of use of soap
for hand washing. Statistically significant value was found between
hand washing and HEV positivity in a study by Surajudeenet al59.
CLINICAL DATA (TABLE: 8)
16 (8%) of the pregnant women had history of blood transfusion and
all of them were in 2nd and 3rd trimester of pregnancy. 30 (15%) and 7
(3.5%) of them had history of jaundice in the patient and family
history of jaundice respectively.
BLOOD GROUP (TABLE: 9)
Majority of the pregnant women had O+ blood group followed by B+
blood group individuals. Other blood groups were between the range of
1% to 7%
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SEROPREVALENCE OF HEV POSITIVITY (TABLE: 10)
In the present study, IgM and IgG seropositivity of
asymptomatic pregnant women were 12 (6%) and 18 (9%)
respectively. Among them only IgM+ cases were 5 (2.5%), only IgG+
cases were 11 (5.5%) and both IgM+&IgG+ were 7 (3.5%).
The results of the present study were similar to 5.62%
seroprevalence of IgG, a report given by Daniel et al (2004) at Vellore
from 600 samples including blood donors, antenatal mothers and from
pre-operative patience29,2.
But this results were much lower than 33.67% seroprevalence of
IgG antibodies in a hospital based study, from north India2.  And other
studies from Pune and Lucknow documented a much higher prevalence
in adult population (40%-50%). But the seroprevalence of this study is
also comparable to the 3.6% seroprevalence of hepatitis E in pregnant
women in Madrid, Spain and 6.6% seroprevalence of IgG antibodies to
HEV reported in pregnant women infected with HIV in Gabon and
central Africa55.
AGE AND HEV POSITIVITY (TABLE: 11)
HEV positivity of pregnant women was seen most commonly in
26-30 fears when compared 21-25 years. Seropositivity of
114
asymptomatic pregnant women, appeared to increase as the age
increases. The above observation was similar to the study results of
Cosme et al, in which he states that there is an increase in
seroprevalence of HEV with age in the pregnant women55 .
GRAVIDA AND HEV POSITIVITY (TABLE:12)
When the seropositivity of pregnant women of different gravida
were compared, majority was observed during their second gravida. In
Primigravida, the seropositivity was 7 (30.4%) which was much less
than the seropositivity of 2nd gravida. This result was similar to the
study done by Cosme et al, where seropositivity of hepatitis E were in
association with number of pregnancythough the reason was not yet
clear55.
EDUCATIONAL STATUS AND HEV POSITIVITY(TABLE: 13
and 3)
Most of the asymptomatic pregnant women (42.5%) in the study
group have studied up to middle school. Majority of the IgM+ cases
and IgG+ cases were seen in the middle school followed by the
primary school. But educational status and HEV positivity were not
statistically significant.
This present study results were similar according to Cosme et al
observation, in which he states that there was no positive association
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with the educational status and HEV seropositivity55. But Sekan et al
study showed education seemed to be the only risk factor for HEV
seroprevalence18,58.
SOCIOECONOMIC STATUS, OCCUPATION AND HEV
POSITIVITY (TABLE: 14)
Among the patients enrolled in the present study, only two
patient was seen in lower socioeconomic status hence much infornation
cannot be obtain. HEV positivity was more seen in the upper lower and
lower middle socioeconomic status. According to Nargis et al
socioeconomic status appeared to be the risk factor for IgG
seroprevalence.
All seropositive cases were seen in the house wife. Because
majority of the study population i.e., 91% were involved in house work
(indoor). According to Alain B. Labriqueet al56 in which he observed >
89% of the women reported their occupation as indoor housework.
OVERCROWDING AND FOOD HABIT WITH HEV
POSITIVITY(TABLE: 15)
Majority of HEV positivity were noted in pregnant women
residing in an overcrowded home. Overcrowding was statistically
significant p value (0.002) with only IgM positive cases and both IgM+
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& IgG positive cases (0.017). The above results coincides with the
study done by Cosme et al, which states that hepatits E exposure was
associated with overcrowding55.
Overall, findings in this results put forward that, in overcrowded
living conditions, hepatitis E virus transmission may be multifactorial
and may include person to person transmission57.
Majority of the pregnant women with HEV positivity were non-
vegetarians. The above results shows that the asymptomatic pregnant
women following Non-vegetarian dietary habit were predominantly
associated with HEV seroprevalence. This high prevalence may be due
to consumption of undercooked meat. According to Rakesh et al HEV-
RNA has been detected from domestic swine in their faeces and also
HEV antibodies have been detected in the sera of cattle, sheep, pigs
and rodents4.
DRINKING WATER AND USE OF BOILED WATER (TABLE:
16)
Majority of the HEV seropositivity were observed in pregnant
women using pump water followed municipal water available inside
their home for drinking purpose
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Similar results was repoted by Zimaity et al in which patients
living in homes that were not connected to a municipal source for
drinking water appeared to have increased risk for HEV infection 58.
USE OF BOILED WATER:
Most of the HEV positive pregnant women were not using
boiled water for drinking. This shows, it may be related to HEV
positivity as boiling can inactivate HEV5.
But from the above result, no positive association was found
between source of drinking water and use of boiled water with HEV
positivity. Similar observation was documented by Cosmeet al55 and
also agrees with results found in other studies18.
TOILET FACILITY AND USE OF SOAP (TABLE: 17)
Among the pregnant women, majority of the seropositive cases
were using common toilet (Indian type). Next most common was seen
in cases who did not have toilet facility and were using open field for
defaecation. Highly significant p value was found HEV seropositivity
and toilet facility.  Similar to the present study result, Surajudeen et al
states that type of toilet was significantly associated with HEV
seroprevalence and found to be more common among people who use
open field for deafecation59.
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USE OF SOAP:
Most of the seropositive cases were noted in the pregnant
women who did not have the habit of hand washing with soap after
using toilet. It was highly significant statistically with the
seroprevalence of HEV antibodies. Similar results was shown by
Surajudeenet al59.
CLINICAL DATA AND BLOOD GROUP (TABLE:18 AND
TABLE:19)
Of the probable risk factors studied, antibodies to HEV was not
associated with history of jaundice in the patients and family history of
jaundice. There was no significant association with blood transfusion
which was similar to the study done by Cosmeet al.55
NUCLEICACID AMPLIFICATION TEST
REVERSE TRANSCRIPTASE PCR
Nested PCR was done to all the IgM positive samples as IgM reaches
peak titer in the first 4 weeks of infection after the onset of disease and
disappears within 3 months in 50% of the patients 5. IgG positive cases
were excluded as they appears after IgM and persist for longer duration
of time even upto 14 years1,5.   Ninety negative cases were also
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included in RT-PCR to look for the window period where the
antibodies would not have mounted to a detectable levels.
Viremia will be first detected by RT-PCR, 22nd day after the
exposure and over a week before onset of disease on 30th day5. A
protracted period of viremia was also observed in small number of
patients who were naturally infected5.
All the IgM positive cases and 90 negative samples were found
to be negative for HEV-RNA. This confirms that no patients were in
the window period or in the active infection.
According to the sociodemographic characteristic with hepatitis
E seropositivity in asymptomatic pregnant women, we found that
hepatitis E virus exposure was positively associated with occupation,
toilet facility, overcrowding and behavioral characteristics such as
habit of hand washing with soap after using toilet and non-vegetarian
diet.
Several of the risk factors assessed in the present study were
interrelated. For illustration, a low level of educational level may be
related with low hygiene practices such as not practicing the habit of
hand washing after using toilet and no toilet facility may be associated
with low socioeconomic status of pregnant women.
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Seropositivity to hepatitis E virus infection was not
statistically associated with age, gravida, source of drinking
water , educational status, socioeconomic status and clinical data
such as past history of jaundice in the patient, family history of
jaundice, blood transfusion and blood group.
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SUMMARY
Asymptomatic pregnant women attending routine antenatal
check up in a tertiary care hospital were enrolled and the prospective
study was conducted between “January 2014 and September 2014”.
Total of 200 pregnant mothers were selected and evaluated by a
questionnaire. ELISA and nucleic acid amplification test were done in
the serum samples to detect anti-HEV antibodies HEV-RNA
respectively.
 Majority (46%) of them were seen in the age group of 21-
25 (mean age 24.55).
 Most of them were in the 2nd and 3rd trimester of
pregnancy.
 Primigravida outnumbered second and multigravida.
 Educational status of most of the pregnant women
(42.5%) was middle school.
 Most of the pregnant women (41.5%) belonged to lower
middle class.
 91% of the asymptomatic women were involved in indoor
housework.
 Majority (69.5%) resided in overcrowded houses and
(93.0%) followed non-vegetarian diet.
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 Municipal water was the main source of drinking water
and 75.7% do not use boiled water for drinking.
 Majority were using common Indian type toilet and 67%
do not have the habit of hand washing.
HEV SEROPREVALENCE:
 In the present study, IgM and IgG seropositivity of
asymptomatic pregnant women were 12 (6%) and 18
(9%) respectively.
 only IgM+ cases were 5 (2.5%), only IgG+ cases were 11
(5.5%) and both IgM+&IgG+ were 7 (3.5%).
 Most of the positive cases were in the age group 26-30.
 Seroprevalence was found to be statistically significant
with overcrowding, type of toilet facility and habit of hand
washing with soap after using toilet.
 Seropositivity was also found to be associated with
increasing age, multigravida, pregnant woman involved in
indoor housework.
 Seroprevalence was not associated with age, educational
level, socioeconomic status, dietary habits, source of
drinking water, use of boiled water, family H/O jaundice,
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past H/O of jaundice in the pregnant women, history of
blood transfusion and blood groups.
 When compared to the PCR results which was done for
90 negative cases and 12 IgM positive cases by ELISA,
no cases were found to be positive for HEV-RNA. This
confirms no viremia in the blood and hence no patients
were in the window period or active infection.
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CONCLUSION
In the present study, IgM and IgG seropositivity of
asymptomatic pregnant women were 12 (6%) and 18 (9%)
respectively. Among them only IgM+ cases were 5 (2.5%), only IgG+
cases were 11 (5.5%) and both IgM+&IgG+ were 7 (3.5%).  Semi
nested Reverse transcriptase PCR was found to be negative in all IgM
positive.
From the present study we conclude that there is very low
prevalence of anti HEV IgM and IgG antibodies among asymptomatic
pregnant women and no cases were found to be positive for HEV-RNA
or in the period of viremia. However these patients have to be screened
periodically as they are high risk for developing fatal fulminant hepatic
failure in their third trimester of pregnancy.
HEV-RNA testing can be considered in patients who are
symptomatic for hepatitis E infection because viremia is the only
marker of infection during the acute phase where anti HEV antibodies
were not in a detectable levels. Also it should be considered in
immunocompromised individuals as seroconversion could be delayed
in these patients.
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As hepatitis E virus spread through faeco-oral contamination, we
should encourage public to adhere to the personal and household
hygiene measures. Conservative control efforts at the community level
such as provision of proper sanitation resources and water
decontamination must also be complemented
Pregnant women are possibly susceptible to hepatitis E
infection and are potentially high risk for fatal fulminant hepatic
failure. Most recent trials of hepatitis E vaccine are certainly
promising, and is found to be very efficacious in a controlled trial.
Hence it can be considered in the most susceptible and high-risk
groups in endemic countries.
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PROFORMA:
DATE: MOBILE:                                                    BLOOD GP:
NAME: OP/IP NO:MICRO ID NO:
AGE: EDUCATION:                                     OCCUPATION:
ADDRESS:
SOCIO ECONOMIC STATUS:
NO. OF PEOPLE RESIDING AT HOME:                                   SQ FT:
TOILET FACILITY: COMMON/ INDIVIDUAL
WATER FACILITY:                                           BOILING WATER: YES/NO
PRACTICE OF HANDWASHING: YES/NO
COMPLAINTS:
GRAVIDA: LMP:                                                    EDD:
PAST OBSTERTIC HISTORY:
H/O: 1.BLOOD TRANSFUSION (YES/NO)
2. JAUNDICE (SELF/FAMILY)
TREATMENT HISTRORY:
IMMUNIZATION HISTORY:
OTHER TEST DONE:
GENERAL EXAMINATION:
PALLOR: YES/NO
ICTERUS: YES/NO
PHYSICAL EXAMINATION:
DATA SHEET
1 2 3 4 5 6 7 8 9 10 11 12
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For 96 well MICROTITRE PLATE
PC- positive control
NC- negative control
IC- internal control
S- Samples
DS-EIA-ANTI-M
NATURE OF THE REAGENTS:
HEV Ag coated strips:
A PC S4 S12 S20 S28 S36 S44 S52 S60 S68 S76 S84
B PC S5 S13 S21 S29 S37 S45 S53 S61 S69 S77 S85
C NC S6 S14 S22 S30 S38 S46 S54 S62 S70 S78 S86
D NC S7 S15 S23 S31 S39 S47 S55 S63 S71 S79 S87
E IC S8 S16 S24 S32 S40 S48 S56 S64 S72 S80 S88
F S1 S9 S17 S25 S33 S41 S49 S57 S65 S73 S81 S89
G S2 S10 S18 S26 S34 S42 S50 S58 S66 S74 S82 S90
H S3 S11 S19 S27 S35 S43 S51 S59 S67 S75 S83 S91
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Polystyrene stripped 96 wells plate (breakable) coated with mix
of recombinant antigens of HEV. Stored at 2-8° C until expiration date.
Sample diluent:
Transparent or slightly opalescent liquid, violet-blue coloured,
sediment may form which completely dissolves at shaking. Preserving
agent: 0.01% thimerosal. Store at 2-8° C until expiration date.
Conjugate concentrated 21-fold:
Monoclonal mouse antibodies against human IgM, labeled
horseradish peroxidase. Transparent or slightly opalescent liquid, light
yellow colored. Preserving agent: 0.04% ProClin 300, 0.04%
gentamycin sulfate. Store at 2-8° C until expiration date in a tightly
sealed vial
Conjugate diluent:
Transparent, yellow liquid at temperature of 2-8° C, opalescent
yellow color liquid at temperature of 18-24°C. Preserving agent:
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Preserving agent: 0.01% thimerosal. Store at 2-8° C until expiration
date in a tightly sealed vial.
Positive control:
Heat inactivated human serum positive for anti-HEV-IgM,
negative for anti-HIV-1,2, HBsAg and anti-HCV. Transparent or
slightly opalescent liquid, red colored. Preserving agent: 0.04%
ProClin 300, 0.1% sodium azide. Store at 2-8°C until expiration date in
a tightly sealed vial.
Negative control:
Heat inactivated human serum positive for anti-HEV-IgM,
negative for anti-HIV-1,2, HBsAg and anti-HCV. Transparent or
slightly opalescent liquid, green colored. Preserving agent: 0.01%
thiomersal , 0.1% sodium azide. Store at 2-8°C until expiration date in
a tightly sealed vial.
Washing solution (concentrated 25 fold)
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Transparent or slightly opalescent liquid, colorless, or pale
yellow, sediment may form that dissolves at 35-39°C and shaking.
Store at 2-8°C until expiration date in a tightly sealed vial.
Substrate buffer:
Citric acid and sodium acetate solution, pH 4.1-4.3, containing
H2O2 . Transparent colorless liquid. Preserving agent: 0.04% ProClin
300. Store at 2-8°C until expiration date in a tightly sealed vial.
TMB concentrated 21- folds:
Solution containing Tetramethylbenzidine (TMB). Transparent
colorless liquid. Store at 2-8°C until expiration date in a tightly sealed
vial.
Stopping reagent:
0.2M/L sulphuric acid solution. Transparent colorless liquid.
Store at 2-8°C until expiration date in a tightly sealed vial.
DS-EIA-ANTI-G
NATURE OF THE REAGENTS:
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HEV Ag coated strips:
Polystyrene stripped 96 wells plate (breakable) coated with mix
of recombinant antigens of HEV. Stored at 2-8° C until expiration date.
Sample diluent:
Transparent or slightly opalescent liquid, violet-blue coloured,
sediment may form which completely dissolves at shaking. Preserving
agent: 0.01% thimerosal. Store at 2-8° C until expiration date.
Conjugate concentrated 21-fold:
Monoclonal mouse antibodies against human IgG, labled
horseradish peroxidase. Transparent or slightly opalescent liquid, light
yellow colored. Preserving agent: 0.04% ProClin 300, 0.04%
gentamycin sulfate. Store at 2-8° C until expiration date in a tightly
sealed vial
Conjugate diluent:
Transparent, yellow liquid at temperature of 2-8° C, opalescent
yellow color liquid at temperature of 18-24°C. Preserving agent:
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Preserving agent: 0.01% thimerosal. Store at 2-8° C until expiration
date in a tightly sealed vial.
Positive control:
Heat inactivated human serum positive for anti-HEV-IgG,
negative for anti-HIV-1,2, HBsAg and anti-HCV. Transparent or
slightly opalescent liquid, red colored. Preserving agent: 0.04%
ProClin 300, 0.1% sodium azide. Store at 2-8°C until expiration date in
a tightly sealed vial.
Negative control:
Heat inactivated human serum positive for anti-HEV-IgG,
negative for anti-HIV-1,2, HBsAg and anti-HCV. Transparent or
slightly opalescent liquid, green colored. Preserving agent: 0.01%
thiomersal, 0.1% sodium azide. Store at 2-8°C until expiration date in a
tightly sealed vial.
Washing solution (concentrated 25 fold)
Transparent or slightly opalescent liquid, colorless, or pale
yellow, sediment may form that dissolves at 35-39°C and shaking.
Store at 2-8°C until expiration date in a tightly sealed vial.
Substrate buffer:
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Citric acid and sodium acetate solution, pH 4.1-4.3, containing
H2O2 . Transparent colorless liquid. Preserving agent: 0.05% ProClin
300. Store at 2-8°C until expiration date in a tightly sealed vial.
TMB concentrated 21- folds:
Solution containing Tetramethylbenzidine (TMB). Transparent
colorless liquid. Store at 2-8°C until expiration date in a tightly sealed
vial.
Stopping reagent:
0.75 M/L sulphuric acid solution. Transparent colorless liquid.
Store at 2-8°C until expiration date in a tightly sealed vial.
SEMI-NESTED PCR KIT FOR HEPATITIS E VIRUS
Kit component for 100 reactions
 RT-PCR master mix – 1ml
 Enzyme mix 100µl
 HEV/IC primer mix 990µl
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 Internal control template 500µl
 HEV positive template 100µl
 Water, nuclease free 1ml
KEY TO MASTER CHART
 BLD GP- BLOOD GROUP
 UN EDU- UN EDUCATED
 HW- HOUSE WIFE
 NO OF PPL- NUMBER OF PEOPLE
 SQ FT- SQUARE FEET
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 IND- INDIVIDUAL (INDIAN) TOILET
 OUT- OPEN FIELD DEAFECATION
 COM- COMMON TOILET (INDIAN TYPE)
 WESTR WESTERN TYPE OF TOILET
 1R1H1K- 1 ROOM, 1HALL, 1 KITCHEN
 MUNI- MUNICIPAL WATER
 TAP OUT- COMMON TAP IN THE STREET
 G2P1- GRAVIDA1-PARA1
 LMP- LAST MENSTRUAL PERIOD
 EDD- EXPECTED DATE OF DELIVERY
 WOG- WEEKS OF GESTATION
 BLD TRANSFUSION- BLOOD TRANSFISION
 FAM HIST- FAMILY HISTORY OF JAUNDICE
 FOOD- FOOD HABIT
 NEG- GEATIVE
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Informed consent form
Information to the subject
You are invited to participate in this study titled “To Find The Prevalence Of
Hepatitis E Virus Infection In Asymptomatic Antenatal Mothers Attending
Routine Antenatal Check Up In A Tertiary Care Hospital”
This study is an interventional one and it involves collecting of around 5 ml
of blood and the general information about you and the facilities in your
house.
This information is collected only for research purpose. The analysis will
show the prevalence rate of Hepatitis E virus infection and the importance of
screening, diagnosis and management about the infection. This study does
not carry any risk to the participant. The benefit will be in the form of
providing information and the importance of early detection, management
and the possible outcome of the infection.
Participation in this study is purely voluntary. If u do not want to provide the
information, you can withdraw from the study.
Refusal to participate will not affect your treatment.
Declaration by the subject
I, -------------------------------- have been explained about the nature and
purpose of the study by the investigator in the language that I best
understood.
I have had the opportunity to ask questions about the study and the
questions I had asked were answered to my satisfaction.
I know that my personal details will be kept confidentially, and I have the
right to withdraw my consent at anytime.
I consent voluntarily to participate in this study.
Name of the subject:
Signature / Thumb impression of the participant:
Name of the investigator:
Investigator’s signature:
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IgG – ELISA KIT
IgG – ELISA
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